by Raynovich Rod | Feb 28, 2013 | BIOgraph
Market Reverses Late in the Day Giving Pause to Euphoria Intuitive Surgical (ISRG $509.89) plunged 11% in final minutes upon disclosure from Bloomberg of a safety probe from U.S. regulators. An FDA survey is trying to determine “whether adverse incident reports...
by Raynovich Rod | Feb 26, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph
Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and...
by Raynovich Rod | Feb 26, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Genomic Health-Good Long Term Value This looks like a good entry point for buying shares of Genomic Health (GHDX $28.50), a molecular diagnostic company focused on personalized medicine for cancer with its oncotype DX invasive breast cancer test.Yesterday the Company...
by Raynovich Rod | Feb 22, 2013 | BIOgraph, Biopharmaceuticals
Technicals Still Rule As Momentum Eases-Reiterate Caution MO favs down: INFI, MDVN, PCYC The Life Science sector is up about 1% after two days of selling on heavy volume. The bellwether ETFs (IBB $145.16) are about 2% off 52 week highs and we do not expect this...
by Raynovich Rod | Feb 19, 2013 | BIOgraph, Biopharmaceuticals
The BIG money in biotech has moved on to new names like Infinity (INFI) up 15 points since December. In the meantime they are moving out of the big winners from 2012 like Alexion (ALXN $83.4) down 3% and Regeneron (REGN $160) down 2.7% . See previous postings. The...
by Raynovich Rod | Feb 15, 2013 | BIOgraph, Macro
The Stock Market Realty Shows In case you missed it stocks lately are being driven by hedge funds and celebrity billionaires who tout their positions. The Icahn vs Ackman drama is the latest high profile realty show featured mainly by CNBC-TV. Biotechnology stocks...
by Raynovich Rod | Feb 14, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Caution is Warranted by Technicals Given the toppiness in the biotechnology sector and the stalling of the IBB ($146), it looks like momentum is waning and some MO stocks favored by BIG money are selling off. Nonetheless we have not made any portfolio recommendations...
by Raynovich Rod | Feb 13, 2013 | Weather//Ski Reports-Western US
Feb. 25 Update No Snow for 8-10 Days Drought article: Thin Snowpack Signals Summer of Fire and Drought – NYTimes.com Snow on the Way -Maybe 12-18 in (Only 8 in.) Storm track variable with ppt levels down a tad. Tuesday still looks good in the Sierras then storm...
by Raynovich Rod | Feb 12, 2013 | Biopharmaceuticals
Sell-Off Evident In Big Winners-Technicals Are Very Important In Here The 2013 rally trickled up today with the DOW and S&P up, but off its highs. NASDAQ is flat. The media trash talk has stoked up with many well known pundits and strategists urging caution but...
by Raynovich Rod | Feb 7, 2013 | 2023-24 Life Science Portfolios, BIOgraph, Macro
Raise a Little Cash as Macro Focus Brings Choppy Action Life Science stocks took a hit today underperforming NASDAQ which was down only 3.35 pts. The biotech sector has been pretty much on a tear since the November bottom as they re-accelerated in mid-December. The...